Sutro Biopharma (STRO) Current Leases (2021 - 2025)

Sutro Biopharma's Current Leases history runs 5 years deep, the most recent figure standing at $7.8 million for Q4 2025.

• In Q4 2025, Current Leases rose 4.05% year-over-year to $7.8 million; the TTM figure through Dec 2025 stood at $7.8 million (up 4.05% YoY), while the FY2025 annual figure was $7.8 million, up 4.05% from the prior year.
• Current Leases came in at $7.8 million for Q4 2025 at Sutro Biopharma, down from $8.0 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $8.1 million in Q2 2025 to a low of $1.0 million in Q4 2021.
• A 5-year average of $5.3 million and a median of $6.3 million in 2023 frame the typical range for Current Leases.
• Across the five-year window, Current Leases soared 429.82% in 2023 and rose 4.05% in 2025, its largest moves.
• Sutro Biopharma's Current Leases stood at $1.0 million in 2021, then soared by 342.14% to $4.6 million in 2022, then soared by 40.02% to $6.4 million in 2023, then grew by 16.51% to $7.5 million in 2024, then climbed by 4.05% to $7.8 million in 2025.
• According to Business Quant data, Current Leases over the past three periods registered $7.8 million, $8.0 million, and $8.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison